Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
isatuximab + bortezomib + lenalidomide + dexamethasone
- Development stage
- Unknown
- Lead developer
- Sanofi
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Subcutaneous, Oral
01
Overview
Isatuximab + bortezomib + lenalidomide + dexamethasone (Isa-VRd) is a quadruplet regimen used for the treatment of multiple myeloma. This combination therapy includes: - **Isatuximab**: A humanized monoclonal antibody that targets a specific extracellular epitope of CD38 receptor, which is widely expressed on plasma cells. It kills myeloma cells through multiple mechanisms including antibody-dependent cellular cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), complement-dependent cytotoxicity (CDC), and direct induction of apoptosis. - **Bortezomib**: A proteasome inhibitor - **Lenalidomide**: An immunomodulatory drug - **Dexamethasone**: A corticosteroid The combination has shown significant efficacy in clinical trials, particularly in newly diagnosed multiple myeloma patients who are ineligible for autologous stem cell transplantation. In the IMROZ phase 3 study, Isa-VRd demonstrated a 40% reduction in the risk of disease progression or death compared to VRd alone, with deep and sustained responses.
- Other names
- isatuximab-irfc + bortezomib + lenalidomide + dexamethasone
02
Targets
PSMB5 (Proteasome subunit beta Type-5)GR (Glucocorticoid receptor)CD38 (Cluster of Differentiation 38)CRBN (Cereblon)
Beyond the preview
Go deeper on isatuximab + bortezomib + lenalidomide + dexamethasone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on isatuximab + bortezomib + lenalidomide + dexamethasone.